Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Cerevel Therapeutics Holdings, Inc. (CERE) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/22/2023 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., November 8, 2022 –"
08/01/2022 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass"
05/10/2022 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents and marketable securities as of March 31, 2022; additional $37.5M from tavapadon risk-sharing arrangement received in April 2022 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass"
03/01/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 Submissions of additional PK/PD data for CVL-231 in schizophrenia accepted for presentation at the Annual Meeting of the American College of Neuropsychopharmacology Conference call and webcast scheduled today at 8:00 a.m. ET CAMBRIDGE, Mass"
08/11/2021 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia Raised $328 million in net proceeds from follow-on offering of common stock and announced redemption of outstanding public warrants Received Fast Track designation and initiated screening in Phase 2a trial of CVL-871 in dementia-related apathy Virtual R&D Update Event scheduled for October 7, 2021 Conference call and webcast scheduled today at 8:00 a.m. EDT CAMBRIDGE, Mass., August 11, 2021 --"
05/17/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
Docs: "Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results"
11/16/2020 8-K Quarterly results
Docs: "Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy